{
  "title": "Members of Congress Question FDA Proposal Designed to Create Liability Shield for Drug and Device Companies",
  "outline": [
    {
      "level": "H3",
      "text": "Members of Congress Question FDA Proposal Designed to Create Liability Shield for Drug and Device Co",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Today Representatives Henry A. Waxman, John D. Dingell, Frank Pallone, Jr., Rosa L.",
      "page": 1
    },
    {
      "level": "H2",
      "text": "DeLauro, and Edward Markey, and Senators Edward M. Kennedy, Patrick J. Leahy, and",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Christopher J. Dodd, questioned the basis for a new Food and Drug Administration (FDA)",
      "page": 1
    },
    {
      "level": "H2",
      "text": "proposal that was apparently designed to shield pharmaceutical and device companies from",
      "page": 1
    },
    {
      "level": "H2",
      "text": "liability for injuries sustained by American consumers as a result of unsafe products.",
      "page": 1
    },
    {
      "level": "H1",
      "text": "“We are concerned that the intent of this proposal is to protect companies in the pharmaceutical",
      "page": 1
    },
    {
      "level": "H2",
      "text": "and device industry from being held liable for marketing products they know are unsafe,” said",
      "page": 1
    },
    {
      "level": "H2",
      "text": "the members in a letter to FDA Commissioner von Eschenbach. “Such a policy change comes",
      "page": 1
    },
    {
      "level": "H2",
      "text": "at the expense of consumers and violates the mission of the FDA.”",
      "page": 1
    },
    {
      "level": "H1",
      "text": "FDA’s proposed rule would amend the regulations that permit companies to promptly update",
      "page": 1
    },
    {
      "level": "H2",
      "text": "their drug and device labels with new safety information without waiting for FDA approval.",
      "page": 1
    },
    {
      "level": "H2",
      "text": "These regulations serve the vitally important public health function of ensuring that patients and",
      "page": 1
    },
    {
      "level": "H2",
      "text": "healthcare providers are made aware of safety risks associated with their medical products at",
      "page": 1
    },
    {
      "level": "H2",
      "text": "the earliest possible moment.",
      "page": 1
    },
    {
      "level": "H1",
      "text": "Given that FDA failed to identify a public health basis for why this lengthy proposal was",
      "page": 1
    },
    {
      "level": "H2",
      "text": "necessary at this point in time, the letter’s authors ask FDA to answer questions justifying the",
      "page": 1
    },
    {
      "level": "H2",
      "text": "expenditure of the agency’s limited resources on this effort.",
      "page": 1
    },
    {
      "level": "H2",
      "text": "Documents and Links",
      "page": 1
    },
    {
      "level": "H2",
      "text": "-  Letter to FDA Commissioner von Eschenbach",
      "page": 1
    },
    {
      "level": "H2",
      "text": "-  Press Release: Members of Congress Question FDA Proposal",
      "page": 1
    }
  ]
}